Brought to you by 
Roche buys Piramed for up to $175mm, gets PI3-K inhibitors
29 Sep 2021
Executive Summary
In its first biopharmaceutical acquisition in exactly one year, Roche has agreed to buy private UK company Piramed (cancer, inflammation, and immune disorder therapeutics) for $160mm cash. Piramed shareholders are also eligible for $15mm in earn-outs should the biotech advance its lead cancer candidate into Phase II trials.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche buys Piramed for up to $175mm, gets PI3-K inhibitors
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice